BMO Capital analyst Matt Borsch raised his price target on Mednax to $58 and kept his Market Perform rating following "solid" Q4 earnings, particularly in light of the "significant volume headwinds for the year as a whole". The analyst also cites a Q1 outlook that reflects a "comparatively stronger start for trends this year", even as EBITDA growth trails the higher volume pace. Borsch adds there is some potential to Mednax's previously announced cost reduction forecasts after the company started a review of clinical cost of service to help improve revenue growth and cost effectiveness.